Pacs Group Inc (PACS) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket
 


Pacs Group Inc   (NYSE: PACS)
    Sector • Healthcare    Industry • Healthcare Facilities
   Industry • Healthcare Facilities
   Sector • Healthcare

Pacs Group Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Pacs Group Inc in the second quarter 2026?
Pacs Group Inc achieved a return on average equity (ROE) of 27 % in its second quarter 2026 a new company high.

While the company's net income was fading, Pacs Group Inc was able to improve its ROE compared to the first quarter 2026.

Within the Healthcare Facilities industry 3 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 474, from total ROE ranking in the first quarter 2026 at 483.

What is ROE?




Return On Equity (Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
Y / Y Equity Change 37.25 % 37.81 % 836.29 % 31.52 % -
Y / Y Net Income Change 49.8 % 184.24 % 65.19 % 222.83 % -
Net Income (TTM) in Millions 269 244 191 168 132
Return On Equity (TTM) 27 % 26.46 % 22.54 % 26.36 % 22.55 %
PACS's Total Ranking # 474 # 483 # 398 # 0 # 0
Equity (TTM) in Millions 1,115 1,042 952 877 813
Seq. Equity Change 7.02 % 9.42 % 8.61 % 7.91 % 7.46 %
Seq. Net Income Change -5.35 % 34.93 % 14.25 % 2.68 % 79.58 %

Return On Equity Company Ranking
Within: No.
Industry # 4
Sector # 60
Overall # 474

Return On Equity Statistics
High Average Low
27 %
21.41 %
9.46 %
(Jun 30 2026)   (Mar 31 2025)





PACS Annual Return On Equity (Dec 31 2025)
2025
(Dec 31 2022)
2024



Total Equity in Millions 952 102 0 0 0
Y / Y Equity Change 836.29 % - - - -
Net Income in Millions 191 150 0 0 0
Y / Y Net Income Change 27.22 % - - - -
Return On Equity 20.1 % 147.94 % - - -





Annual Roe Comment
In 2025 ROE fell to 20.1 %, despite net income growth.


More Return On Equity Ratios
Healthcare Facilities Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
PACS's' Return on Equity at Yahoo Finance
PACS's Roe Ratio versus Healthcare Facilities Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for PACS's Competitors
Subscribers only: Roe for Pacs Group Inc 's Suppliers
Subscribers only: Return On Equity for PACS's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE
Oramed Pharmaceuticals Inc  73.03 %
Tg Therapeutics Inc   72.30 %
Idexx Laboratories Inc  71.96 %
Elite Pharmaceuticals Inc   71.10 %
Zoetis Inc   68.87 %
Rallybio Corporation  68.56 %
Earth Science Tech Inc   66.17 %
Aurinia Pharmaceuticals Inc   59.00 %
Vaxart Inc   53.04 %
Qhslab Inc   51.21 %
Tenet Healthcare Corp  50.64 %
Nrc Health  48.29 %
Concentra Group Holdings Parent Inc   48.13 %
Bristol myers Squibb Company  46.65 %
Agilent Technologies inc   41.99 %
Eton Pharmaceuticals Inc   40.13 %
Adma Biologics Inc   39.59 %
Dexcom Inc   36.25 %
Transmedics Group Inc   33.37 %
Arcutis Biotherapeutics Inc   32.92 %
Caredx Inc   32.81 %
Zevra Therapeutics Inc   32.56 %
Acadia Pharmaceuticals Inc   32.39 %
Pro dex Inc   31.96 %
Protalix Biotherapeutics inc   31.61 %
Illumina Inc   31.08 %
Innoviva Inc   30.03 %
Phibro Animal Health Corporation  29.66 %
Chemed Corporation  29.45 %
Solventum Corporation  28.96 %


Date modified: 2026-09-26T07:42:46+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.